Latest Share Based Payments News

Page 7 of 17
Pentanet Limited has reported its first-ever positive EBITDA of $1.4 million for FY25, alongside an 8% revenue increase and a significant expansion of its 5G Fixed Wireless network covering a quarter of its tower footprint.
Sophie Babbage
Sophie Babbage
29 Aug 2025
WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Rent.com.au Limited reported a $3.69 million net loss for FY25 amid modest revenue growth, while securing significant funding to scale its RentBond® product and reshaping its leadership team.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Clean TeQ Water Limited reported a reduced loss of $2.8 million for FY25 and increased its stake in Go2Lithium Inc to 60%, marking a strategic shift as it advances water treatment and critical metals recovery projects worldwide.
Victor Sage
Victor Sage
28 Aug 2025
Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.
Victor Sage
Victor Sage
28 Aug 2025
NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.
Ada Torres
Ada Torres
28 Aug 2025
Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.
Ada Torres
Ada Torres
28 Aug 2025
Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.
Victor Sage
Victor Sage
28 Aug 2025
Mad Paws Holdings reported a $12.27 million loss for FY25, deepening from last year, as it divests its Pet Chemist business and agrees to a $62 million acquisition by Rover Group.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Entertainment Rewards Ltd reported a 12.7% increase in operating revenue for FY2025, driven by growth in key segments, but posted a wider net loss of $9.7 million amid higher expenses and a major convertible loan amendment.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.
Ada Torres
Ada Torres
28 Aug 2025